SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-12-220306
Filing Date
2012-05-09
Accepted
2012-05-09 07:55:15
Documents
12
Period of Report
2012-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d329373d10q.htm 10-Q 265461
2 BIOPHARMACEUTICAL SERVICES AGREEMENT d329373dex101.htm EX-10.1 380770
3 AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENT d329373dex102.htm EX-10.2 10397
4 SECTION 302 CEO CERTIFICATION d329373dex311.htm EX-31.1 8205
5 SECTION 302 CFO CERTIFICATION d329373dex312.htm EX-31.2 8162
6 SECTION 906 CEO AND CFO CERTIFICATION d329373dex321.htm EX-32.1 4438
12 GRAPHIC g329373gr005.jpg GRAPHIC 14774
  Complete submission text file 0001193125-12-220306.txt   1700985

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT geva-20120331.xml EX-101.INS 125637
8 XBRL TAXONOMY EXTENSION SCHEMA geva-20120331.xsd EX-101.SCH 10016
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE geva-20120331_cal.xml EX-101.CAL 28408
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE geva-20120331_lab.xml EX-101.LAB 92881
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE geva-20120331_pre.xml EX-101.PRE 59826
Mailing Address 128 SPRING STREET SUITE 520 LEXINGTON MA 02421
Business Address 128 SPRING STREET SUITE 520 LEXINGTON MA 02421 (781) 357-9900
SYNAGEVA BIOPHARMA CORP (Filer) CIK: 0000911326 (see all company filings)

IRS No.: 561808663 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23155 | Film No.: 12823802
SIC: 2836 Biological Products, (No Diagnostic Substances)